Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
European viper venom antiserum (equine)
- Development stage
- Unknown
- Lead developer
- Institute of Immunology
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
European viper venom antiserum (equine), historically known as the Zagreb antivenom, is an equine-derived passive immunotherapeutic agent developed by the Institute of Immunology in Zagreb, Croatia. It consists of purified F(ab')2 fragments of immunoglobulins obtained from horses hyperimmunized with the venom of the nose-horned viper (*Vipera ammodytes*). This polyvalent antivenom is indicated for the treatment of envenomation in both humans and animals caused by European vipers of the genus *Vipera*, specifically protecting against the venoms of five species: *Vipera ammodytes*, *Vipera berus*, *Vipera aspis*, *Vipera xanthina*, and *Vipera lebetina*. It works by binding and neutralizing the toxic enzymatic and non-enzymatic components of the venoms. Although production was temporarily halted, a revitalization project is underway to construct a new manufacturing facility in Rugvica, Croatia, to resume production of this critical biological product.
- Brand names
- European Viper Venom Antiserum
- Other names
- European viper antiserumEuropean viper snake venom antiserumEuropean viper venom antiserumZagreb antivenomviper venom antiserum, European (equine)
02
Targets
Vipera aspis venom toxinsVipera ammodytes venom toxinsMontivipera xanthina venom toxins
Beyond the preview
Go deeper on European viper venom antiserum (equine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on European viper venom antiserum (equine).